Arcticzymes Technologies ASA

OL:AZT Norway Biotechnology
Market Cap
$91.44 Million
Nkr1.04 Billion NOK
Market Cap Rank
#19361 Global
#82 in Norway
Share Price
Nkr20.40
Change (1 day)
-1.92%
52-Week Range
Nkr15.00 - Nkr30.90
All Time High
Nkr111.00
About

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays for the removal… Read more

Arcticzymes Technologies ASA (AZT) - Net Assets

Latest net assets as of December 2025: Nkr338.47 Million NOK

Based on the latest financial reports, Arcticzymes Technologies ASA (AZT) has net assets worth Nkr338.47 Million NOK as of December 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr361.41 Million) and total liabilities (Nkr22.94 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets Nkr338.47 Million
% of Total Assets 93.65%
Annual Growth Rate 7.28%
5-Year Change 38.24%
10-Year Change 397.12%
Growth Volatility 83.96

Arcticzymes Technologies ASA - Net Assets Trend (2002–2025)

This chart illustrates how Arcticzymes Technologies ASA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Arcticzymes Technologies ASA (2002–2025)

The table below shows the annual net assets of Arcticzymes Technologies ASA from 2002 to 2025.

Year Net Assets Change
2025-12-31 Nkr338.47 Million +4.68%
2024-12-31 Nkr323.35 Million +4.54%
2023-12-31 Nkr309.30 Million +8.63%
2022-12-31 Nkr284.74 Million +16.29%
2021-12-31 Nkr244.84 Million +24.71%
2020-12-31 Nkr196.33 Million +322.39%
2019-12-31 Nkr46.48 Million -13.77%
2018-12-31 Nkr53.90 Million +20.27%
2017-12-31 Nkr44.81 Million -34.18%
2016-12-31 Nkr68.08 Million -21.52%
2015-12-31 Nkr86.75 Million -12.26%
2014-12-31 Nkr98.87 Million +132.50%
2013-12-31 Nkr42.52 Million +94.10%
2012-12-31 Nkr21.91 Million -52.20%
2011-12-31 Nkr45.83 Million +25.96%
2010-12-31 Nkr36.39 Million -40.50%
2009-12-31 Nkr61.15 Million -61.60%
2008-12-31 Nkr159.27 Million -21.94%
2007-12-31 Nkr204.04 Million +93.02%
2006-12-31 Nkr105.71 Million -17.26%
2005-12-31 Nkr127.76 Million +159.75%
2004-12-31 Nkr49.18 Million -13.34%
2003-12-31 Nkr56.75 Million -15.58%
2002-12-31 Nkr67.23 Million --

Equity Component Analysis

This analysis shows how different components contribute to Arcticzymes Technologies ASA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 2162600000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings Nkr21.63 Million 6.39%
Other Components Nkr316.84 Million 93.61%
Total Equity Nkr338.47 Million 100.00%

Arcticzymes Technologies ASA Competitors by Market Cap

The table below lists competitors of Arcticzymes Technologies ASA ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Arcticzymes Technologies ASA's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 323,350,000 to 338,467,000, a change of 15,117,000 (4.7%).
  • Net income of 9,881,000 contributed positively to equity growth.
  • Other factors increased equity by 5,236,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income Nkr9.88 Million +2.92%
Other Changes Nkr5.24 Million +1.55%
Total Change Nkr- 4.68%

Book Value vs Market Value Analysis

This analysis compares Arcticzymes Technologies ASA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.08x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 5.44x to 3.08x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2002-12-31 Nkr3.75 Nkr20.40 x
2003-12-31 Nkr3.16 Nkr20.40 x
2004-12-31 Nkr1.02 Nkr20.40 x
2005-12-31 Nkr6.92 Nkr20.40 x
2006-12-31 Nkr4.92 Nkr20.40 x
2007-12-31 Nkr8.76 Nkr20.40 x
2008-12-31 Nkr6.33 Nkr20.40 x
2009-12-31 Nkr2.40 Nkr20.40 x
2010-12-31 Nkr1.43 Nkr20.40 x
2011-12-31 Nkr1.53 Nkr20.40 x
2012-12-31 Nkr0.68 Nkr20.40 x
2013-12-31 Nkr1.07 Nkr20.40 x
2014-12-31 Nkr2.28 Nkr20.40 x
2015-12-31 Nkr1.94 Nkr20.40 x
2016-12-31 Nkr1.50 Nkr20.40 x
2017-12-31 Nkr0.98 Nkr20.40 x
2018-12-31 Nkr1.13 Nkr20.40 x
2019-12-31 Nkr0.93 Nkr20.40 x
2020-12-31 Nkr3.96 Nkr20.40 x
2021-12-31 Nkr4.84 Nkr20.40 x
2022-12-31 Nkr5.63 Nkr20.40 x
2023-12-31 Nkr6.08 Nkr20.40 x
2024-12-31 Nkr6.33 Nkr20.40 x
2025-12-31 Nkr6.63 Nkr20.40 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Arcticzymes Technologies ASA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 2.92%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 8.77%
  • • Asset Turnover: 0.31x
  • • Equity Multiplier: 1.07x
  • Recent ROE (2.92%) is above the historical average (-27.87%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2002 -0.96% -9.22% 0.91x 0.11x Nkr-7.37 Million
2003 -17.33% -13.60% 1.10x 1.15x Nkr-15.51 Million
2005 -12.09% -22.05% 0.50x 1.10x Nkr-28.22 Million
2006 -25.21% -36.53% 0.59x 1.17x Nkr-37.23 Million
2007 -9.15% -25.49% 0.33x 1.08x Nkr-39.07 Million
2008 -32.76% -100.92% 0.28x 1.18x Nkr-68.11 Million
2009 -162.49% -412.76% 0.26x 1.51x Nkr-105.49 Million
2010 -78.44% -110.16% 0.38x 1.90x Nkr-32.18 Million
2011 -45.52% -87.28% 0.41x 1.28x Nkr-24.52 Million
2012 -117.33% -113.24% 0.67x 1.56x Nkr-26.39 Million
2013 -54.91% -103.53% 0.41x 1.29x Nkr-27.06 Million
2014 -22.34% -66.59% 0.30x 1.13x Nkr-31.84 Million
2015 -20.11% -32.55% 0.53x 1.17x Nkr-25.97 Million
2016 -30.34% -28.48% 0.84x 1.27x Nkr-27.23 Million
2017 -56.55% -37.40% 1.08x 1.40x Nkr-29.35 Million
2018 -26.38% -20.95% 0.98x 1.28x Nkr-19.29 Million
2019 -14.15% -8.27% 1.00x 1.72x Nkr-10.90 Million
2020 42.76% 88.95% 0.42x 1.14x Nkr63.68 Million
2021 18.94% 36.24% 0.45x 1.16x Nkr21.90 Million
2022 11.54% 23.99% 0.43x 1.12x Nkr4.39 Million
2023 6.28% 16.33% 0.35x 1.10x Nkr-11.50 Million
2024 2.62% 8.12% 0.30x 1.06x Nkr-23.87 Million
2025 2.92% 8.77% 0.31x 1.07x Nkr-23.97 Million

Industry Comparison

This section compares Arcticzymes Technologies ASA's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $66,984,106
  • Average return on equity (ROE) among peers: -131.37%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Arcticzymes Technologies ASA (AZT) Nkr338.47 Million -0.96% 0.07x $76.32 Million
Arctic Bioscience AS (ABS) $287.28 Million -11.84% 0.14x $3.71 Million
Aqua Bio Technology ASA (ABTEC) $8.32 Million -176.71% 0.95x $7.08 Million
Circa Group AS (CIRCA) $41.74 Million -16.77% 0.13x $3.57 Million
Circio Holding ASA (CRNA) $-98.54 Million 0.00% 0.00x $16.90 Million
Exact Therapeutics AS (EXTX) $42.24 Million -35.10% 0.23x $3.19 Million
Lytix Biopharma AS (LYTIX) $107.89 Million -87.37% 0.36x $32.31 Million
PCI Biotech Holding ASA (PCIB) $57.40 Million -95.98% 0.11x $432.13K
SoftOx Solutions AS (SOFTX) $16.01 Million -444.47% 3.86x $12.63 Million
Thor Medical ASA (TRMED) $140.52 Million -314.06% 1.11x $48.68 Million